![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SERPINC1 |
Gene summary for SERPINC1 |
![]() |
Gene information | Species | Human | Gene symbol | SERPINC1 | Gene ID | 462 |
Gene name | serpin family C member 1 | |
Gene Alias | AT3 | |
Cytomap | 1q25.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | A0A024R944 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
462 | SERPINC1 | NAFLD1 | Human | Liver | NAFLD | 1.84e-10 | 5.02e-01 | -0.04 |
462 | SERPINC1 | HCC1_Meng | Human | Liver | HCC | 5.34e-48 | 2.70e-02 | 0.0246 |
462 | SERPINC1 | HCC2_Meng | Human | Liver | HCC | 1.07e-06 | -3.21e-01 | 0.0107 |
462 | SERPINC1 | HCC1 | Human | Liver | HCC | 1.66e-26 | 4.48e+00 | 0.5336 |
462 | SERPINC1 | HCC2 | Human | Liver | HCC | 2.78e-32 | 3.34e+00 | 0.5341 |
462 | SERPINC1 | Pt13.a | Human | Liver | HCC | 5.08e-66 | 1.02e+00 | 0.021 |
462 | SERPINC1 | Pt13.b | Human | Liver | HCC | 2.44e-86 | 7.49e-01 | 0.0251 |
462 | SERPINC1 | Pt13.c | Human | Liver | HCC | 9.15e-30 | 1.06e+00 | 0.0076 |
462 | SERPINC1 | Pt14.a | Human | Liver | HCC | 6.44e-06 | 1.39e-01 | 0.0169 |
462 | SERPINC1 | Pt14.b | Human | Liver | HCC | 8.83e-25 | 6.85e-01 | 0.018 |
462 | SERPINC1 | Pt14.d | Human | Liver | HCC | 3.78e-08 | 3.28e-01 | 0.0143 |
462 | SERPINC1 | S029 | Human | Liver | HCC | 1.47e-07 | 3.60e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00316677 | Liver | NAFLD | response to nutrient levels | 85/1882 | 474/18723 | 8.23e-08 | 7.09e-06 | 85 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:0072376 | Liver | NAFLD | protein activation cascade | 8/1882 | 12/18723 | 3.51e-06 | 1.40e-04 | 8 |
GO:0072378 | Liver | NAFLD | blood coagulation, fibrin clot formation | 7/1882 | 10/18723 | 9.36e-06 | 3.02e-04 | 7 |
GO:00075844 | Liver | NAFLD | response to nutrient | 36/1882 | 174/18723 | 2.06e-05 | 5.78e-04 | 36 |
GO:0002526 | Liver | NAFLD | acute inflammatory response | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SERPINC1 | SNV | Missense_Mutation | novel | c.1295T>C | p.Val432Ala | p.V432A | P01008 | protein_coding | tolerated(0.23) | benign(0.395) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SERPINC1 | SNV | Missense_Mutation | c.781T>C | p.Phe261Leu | p.F261L | P01008 | protein_coding | deleterious(0.03) | probably_damaging(0.972) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SERPINC1 | SNV | Missense_Mutation | novel | c.1357N>G | p.Ile453Val | p.I453V | P01008 | protein_coding | tolerated(0.13) | benign(0.084) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | c.1232N>T | p.Gly411Val | p.G411V | P01008 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
SERPINC1 | SNV | Missense_Mutation | c.67N>T | p.Leu23Phe | p.L23F | P01008 | protein_coding | tolerated(0.08) | benign(0.34) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
SERPINC1 | SNV | Missense_Mutation | rs373515340 | c.1067G>A | p.Arg356His | p.R356H | P01008 | protein_coding | deleterious(0) | benign(0.034) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | c.539G>A | p.Gly180Glu | p.G180E | P01008 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SERPINC1 | SNV | Missense_Mutation | rs199895690 | c.302N>T | p.Ser101Phe | p.S101F | P01008 | protein_coding | deleterious(0.02) | benign(0.077) | TCGA-D5-7000-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | c.930N>G | p.Asp310Glu | p.D310E | P01008 | protein_coding | tolerated(0.12) | probably_damaging(0.982) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
SERPINC1 | SNV | Missense_Mutation | c.347N>T | p.Ser116Phe | p.S116F | P01008 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | Unfractionated heparin | |||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | SULODEXIDE | SULODEXIDE | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | activator | CHEMBL1201476 | ENOXAPARIN SODIUM | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | Sulodexide | SULODEXIDE | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | FONDAPARINUX | FONDAPARINUX | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | RO-14 | |||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | ENOXAPARIN | ENOXAPARIN | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | avatrombopag | AVATROMBOPAG | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | Avatrombopag | AVATROMBOPAG | ||
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | Heparin Calcium |
Page: 1 2 3 4 5 6 |